Nanotechnology Now - Press Release: "New Funding Opportunities in Cancer Nanotechnology"

Home > Press > New Funding Opportunities in Cancer Nanotechnology

Abstract:
The National Cancer Institute is currently soliciting proposals for two funding opportunities in cancer nanotechnology through the SBIR & STTR Programs:

New Funding Opportunities in Cancer Nanotechnology

Bethesda, MD | Posted on September 20th, 2012

• SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44)
RFA Number: RFA-CA-12-023
Application Receipt Date: November 6, 2012; March 6, 2013

• Small Business Innovation Research (SBIR) Program Contract Solicitation (PHS 2013-1)
Notice Number: NOT-OD-12-137
Application Receipt Date: November 13, 2012
Note: numerous relevant funding opportunities are included under this solicitation

To learn more about the NCI SBIR Program, benefits to applying, and eligibility criteria, visit: www.sbir.cancer.gov

Funding opportunities are available through the National Institutes of Health for institutions and organizations addressing problems in biology and medicine:

• Clinical Utility of Extracellular RNA for Therapy Development (UH2/UH3)
RFA Number: RFA-RM-12-014
Application Receipt Date: November 13, 2012

• Reference Profiles of Human Extracellular RNA (U01)
RFA Number: RFA-RM-12-011
Application Receipt Date: November 13, 2012

• Extracellular RNA Biogenesis, Biodistribution, Uptake, and Effector Function (U19)
RFA Number: RFA-RM-12-012
Application Receipt Date: November 13, 2012

• Clinical Utility of Extracellular RNA for Biomarker Development (UH2/UH3)
RFA Number: RFA-RM-12-013
Application Receipt Date: November 13, 2012

• Exploratory Developmental Bioengineering Research Grants (EBRG) [R21]
Notice Number: PA-12-284
*Reissue of PA-10-010
Application Receipt Dates: January 25, 2013

• NIH Director's Early Independence Awards (DP5)
RFA Number: RFA-RM-12-018
Application Receipt Date: January 30, 2013

Many other funding opportunities related to cancer nanotechnology are listed at: nano.cancer.gov/collaborate/funding/.

####

About The National Cancer Institute (NCI)
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: